GYRE (Gyre Therapeutics) Tariff Resilience Score: 5/10 (As of Jul. 03, 2026)


GYRE Gyre Therapeutics Inc GYRE
43 GF Score
Price $7.36
GF Value $9.81
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Gyre Therapeutics Tariff Resilience Score?

Gyre Therapeutics GYRE +12.58% 43 Tariff Resilience Score is 5 as of Jul. 03, 2026. GuruFocus rates GYRE with a GF Score™ of 43/100 and a GF Value™ of $9.81 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,373 Biotechnology companies, Gyre Therapeutics ranks better than 62.27% on this metric.

Gyre Therapeutics has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Gyre Therapeutics has Gyre Therapeutics relies on global supply chains for raw materials and distribution. The pharmaceutical industry can face tariffs on raw materials, but often benefits from exemptions. Mitigation strategies include alternative suppliers and pricing power, but exposure remains moderate.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Gyre Therapeutics might have Average Resilient.

Gyre Therapeutics  (NAS:GYRE) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Gyre Therapeutics Tariff Resilience Score Related Terms

GYRE vs RLMD, ACRS, SGP: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Gyre Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gyre Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's Tariff Resilience Score falls into.


GYRE
43GF Score
Gyre Therapeutics Inc GYRE
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Gyre Therapeutics (GYRE) has a Tariff Resilience Score of 5 as of Jul. 03, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Gyre Therapeutics ranks #518 out of 1373 companies in the Biotechnology industry, placing it in the top 37.7%.
Is Gyre Therapeutics' Tariff Resilience Score too high?
Gyre Therapeutics' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Gyre Therapeutics' value of 5 is 25% above this industry median. Based on the distribution chart, Gyre Therapeutics ranks #518 out of 1373 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Gyre Therapeutics has a GF Score™ of 43/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' Tariff Resilience Score compare to RLMD and ACRS?
According to the Biotechnology industry distribution chart, Gyre Therapeutics ranks #518 out of 1373 companies for Tariff Resilience Score. This puts Gyre Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Gyre Therapeutics' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gyre Therapeutics's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gyre Therapeutics's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Modestly Undervalued. The stock's GF Value™ is $9.81, compared to a current price of $7.36 — trading 25% below its estimated fair value. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Gyre Therapeutics' overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current Tariff Resilience Score is 5 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gyre Therapeutics (GYRE) Overvalued in 2026?

Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued. The current stock price of $7.36 is trading 25% below its estimated GF Value™ of $9.81. GuruFocus considers Gyre Therapeutics to be Modestly Undervalued.

Key valuation signals for GYRE:

  • Tariff Resilience Score: 5
  • GF Value™: $9.81 vs. price of $7.36 (25% below fair value)
  • GF Score™: 43/100 with 2 warning signs
  • Industry Position: 25% above the Biotechnology median (#518 of 1373)

No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gyre Therapeutics Business Description

Other Exchanges L9S:Germany
Address 12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
43GF Score

Get the complete analysis for GYRE

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.36
Price
$9.81
GF Value